Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych: tumour targeting

Sortuj według:

Ogranicz wyniki do:

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

A recently developed approach in tumor therapy using Salmonella

100%

Gharbavi M., Karimkhanlooei G., Amani J., Kashiazari P., Sharafi A.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

2020

tom 101

nr 3

Salmonella and cancer: from pathogens to therapeutics

100%

Chorobik P., Czaplicki D., Ossysek K., Bereta J.

Acta Biochimica Polonica

2013

tom 60

nr 3

Bacterial cancer therapy is a concept more than 100 years old - yet, all things considered, it is still in early development. While the use of many passive therapeutics is hindered by the complexity of tumor biology, bacteria offer unique features that can overcome these limitations. Microbial metabolism, motility and sensitivity can lead to site-specific treatment, highly focused on the tumor and safe to other tissues. Activation of tumor-specific immunity is another important mechanism of such therapies. Several bacterial strains have been evaluated as cancer therapeutics so far, Salmonella Typhimurium being one of the most promising. S. Typhimurium and its derivatives have been used both as direct tumoricidal agents and as cancer vaccine vectors. VNP20009, an attenuated mutant of S. Typhimurium, shows significant native toxicity against murine tumors and was studied in a first-in-man phase I clinical trial for toxicity and anticancer activity. While proved to be safe in cancer patients, insufficient tumor colonization of VNP20009 was identified as a major limitation for further clinical development. Antibody-fragment-based targeting of cancer cells is one of the few approaches proposed to overcome this drawback.

Antitumour activity of Salmonella typhimurium VNP20047 in B16[F10] murine melanoma model

100%

Jazowiecka-Rakus J., Szala S.

Acta Biochimica Polonica

2004

tom 51

nr 3

A tumour therapy is proposed based on attenuated Salmonella typhimurium VNP20047 expressing the Escherichia coli cytosine deaminase gene. VNP20047 was administered intravenously to B16(F10) melanoma-bearing C57BL/6 mice. VNP20047 proliferated within tumours and livers regardless of the initial inoculum dose. After 10 days the number of bacteria increased in livers up to 4.2 x 106 cfu/g and decreased in tumours down to 5.9 x 106 cfu/g. VNP20047 at 1 x 105 cfu/mouse, when combined with 5-fluorocytosine, inhibited tumour growth by 85% without prolonging animal survival. Histology studies revealed severe lesions in tumours and livers. These data suggest that S. typhimurium VNP20047 induced inflammatory responses, even though the strain was attenuated.

Ograniczanie wyników

2 Acta Biochimica Polonica

1 BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

1 Amani J.

1 Bereta J.

1 Chorobik P.

1 Czaplicki D.

1 Gharbavi M.

1 Jazowiecka-Rakus J.

1 Karimkhanlooei G.

1 Kashiazari P.

1 Ossysek K.

1 Sharafi A.

1 Szala S.

1 2020

1 2013

1 2004

Wyniki wyszukiwania

A recently developed approach in tumor therapy using Salmonella

Salmonella and cancer: from pathogens to therapeutics

Antitumour activity of Salmonella typhimurium VNP20047 in B16[F10] murine melanoma model